---
search:
  boost: 3
---

# Monoclonal Antibodies-Anti-IL/Anti-IgE

This is a subcategory of Respiratory Agents.

## Decision Trees

- [Respiratory - Monoclonal Antibodies - Anti-IL/Anti-IgE- Non-Preferred Agents – Nucala, Tezspire](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUOEwzQ1RWTklSTjVVSFRKQTgwVE9SRzVWNSQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Respiratory - Monoclonal Antibodies - Anti-IL/Anti-IgE- Preferred Agent - Dupixent](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUMkU0QlpZNDkxTkpDRUNaRjBaU1YyUDNLMSQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Respiratory - Monoclonal Antibodies - Anti-IL / Anti-IgE - Preferred Agents (PA) – Fasenra, Xolair](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUQVpOMlBRS0RSQjlXV0tZMFZIVjdTNUpRMyQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred              | Generic Name | Quantity | Time (Days) |
|:-----------------------|:-------------|:--------:|:-----------:|
| Fasenra <sup>PA</sup>  |              |          |             |
| Dupixent <sup>PA</sup> |              |          |             |
| Xolair <sup>PA</sup>   |              |          |             |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
|:--------------|:-------------|:--------:|:-----------:|
| Nucala        |              |          |             |
| Tezspire      |              |          |             |

## Authorizations

**Length of Authorizations**: Initial: 180 days; Subsequent: 365 days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Clinical PA

Clinical PA Criteria

-   Must be prescribed by or in consultation with an applicable specialist (i.e., allergist/immunologist, pulmonologist, or otolaryngologist)
-   For **Asthma** – Must have had uncontrolled asthma symptoms and/or exacerbations despite at least **30 days** with:
    -   Medium dose preferred ICS/LABA inhaler for 6 years and older **OR** medium dose preferred ICS/LABA inhaler with tiotropium or high dose ICS/LABA inhaler if 12 years and older**
-   For **Chronic Rhinosinusitis with Nasal Polyposis** – Must have had an inadequate clinical response of at least **30 days** to at least **one oral** corticosteroid AND **one nasal** corticosteroid spray
-   For **Chronic Urticaria** – Must have had an inadequate clinical response to at least **14 days** with at least **two different** antihistamines

[**ICS/LABA Dose Level Chart](https://special-spoon-f542dccd.pages.github.io/Pharmacist%20Reference%20Guide/Clinical%20and%20PA%20Notes/Immunomodulators/Respiratory%20Agents%20-%20Monoclonal%20Antibodies/)

### Non-Preferred

Non-Preferred Criteria

-   Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    -   For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
-   Must have had an inadequate clinical response of at least **90 days** with at least **one preferred** drug
    -   For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    -   For non-preferred brand names that have preferred generics, requests must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring (i.e., PFT improvement, reduced affected BSA)

## Links

[Denial Language (Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com.mcas.ms/:w:/r/personal/rachel_carpenter_gainwelltechnologies_com/_layouts/15/Doc.aspx?sourcedoc=%7B73347C85-1D40-4514-80E9-9628185B51B4%7D&file=Denial%20Language%20Updated%2001012024.docx&action=embedview&mobiledirect=true&wdStartOn=98){:target="_blank" rel="noopener"}

[Criteria](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20criteria%20effective%2001.01.2024.pdf#page=102){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20effective%2001.01.2024.pdf#page=32){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/Quantity%20Limits.pdf){ :target="_blank" rel="noopener"}
